Korean J Otolaryngol-Head Neck Surg.
1998 Nov;41(11):1446-1453.
Amplification of int-2 in Head and Neck Squamous Cell Carcinomas and Adjacent Mucosa
- Affiliations
-
- 1Department of Otolaryngology- Head and Neck Surgery, Gachon Medical College Gil Medical Center, Incheon, Korea.
- 2Department of Otolaryngology-Head and Neck Surgery, College of Medicine, Korea University, Seoul, Korea.
Abstract
-
BACKGROUND AND OBJECTIVES: It is important to identify potential biomarkers of tumorigenesis that can be utilized on histologically normal epithelia to determine the level of risk of tumor development. With the goal of possibly identifying a biomarker for the process of development of head and neck cancer, the amplification of int-2 was observed in patients with head and neck squamous cell carcinoma.
MATERIALS AND METHODS
Fluorescence in situ hybridization using cosmid int-2 probe was performed on paraffin-embedded specimens from tumor and tumor-adjacent and tumor-distant epithelia of 20 patients. Buccal mucosa of cancer-free subjects who smoked and did not smoke cigarettes were used as control. Dot blot hybridization using digoxigenin-labeled int-2 probe was also performed on the frozen tissue from tumor and tumor-adjacent epithelia of 14 patients.
RESULTS
In in situ hybridization, buccal epithelia of cancer-free subjects who smoked and did not smoke cigarettes, and tumor-distant epithelia of the patients with head and neck squamous cell carcinoma showed no int-2 amplification. However, eleven of tumor tissue (55%) and five of tumor-adjacent epithelia (25%) in 20 cases showed int-2 amplification. In dot blot hybridization, five tumor tissue (35.7%) and 2 tumor-adjacent epithelia (14.3%) in 14 cases, of which tumor tissue were all found to have int-2 amplification, showed int-2 amplification.
CONCLUSION
The amplification of int-2 in the tumor tissue and the tumor-adjacent epithelia of the same cases supports the concept of field cancerization or clonal extension. Such genotype parameters may provide a genetic basis for the development of early recurrence or second primary tumors after therapeutic treatment of head and neck squamous cell carcinomas.